Pfizer’s RSV Vaccine:
The Food and Drug Administration (FDA) has granted approval to Pfizer’s vaccine, Abrysvo, aimed at safeguarding new-borns from respiratory syncytial virus (RSV) by vaccinating pregnant individuals during the latter stages of pregnancy.
- Abrysvo has been authorized for use in adults aged 60 and above to protect them from RSV.
- The vaccine generates passive immunity by producing antibodies against RSV in pregnant individuals, which are then passed on to their foetuses in the uterus.
- Abrysvo’s approval is based on its demonstrated effectiveness in reducing the risk of severe lower respiratory tract disease caused by RSV in new-borns.
- However, concerns have been raised about potential preterm births in response to the vaccine, similar to issues seen with another competitor vaccine.
Respiratory syncytial virus (RSV) infection:
- Respiratory syncytial virus (RSV) infection is a common respiratory illness that primarily affects infants, young children, and older adults.
- RSV belongs to the family of viruses called Paramyxoviridae and is a leading cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, especially in children under the age of two.
- The virus spreads through respiratory droplets when an infected person coughs or sneezes, and it can also be transmitted through direct contact with contaminated surfaces.